EL7.AI
Strategy BuilderCOT DataAdvanced NewsResearchNewEarnings CalendarEconomic Calendar
We use cookiesPrivacy Policy
EL7.AIEL7.AI

AI Financial Intelligence
Professional analysis of central bank decisions

© 2026 EL7.AI. All rights reserved.

Markets

  • News
  • Forex
  • Stocks
  • Crypto
  • Gold
  • Commodities
  • Indices
  • ETFs

Analysis

  • Fed
  • ECB
  • BLS
  • COT
  • Economic Calendar

Learn

  • Service Guide
  • Oil

Company

  • About
  • Contact
  • Data Methodology
  • AI Disclosure
  • Pricing
  • Enterprise
  • Terms
  • Privacy
  • Security
  • WhatsApp
Status data is currently unavailable

The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

Home
Stocks
AMETEK, Inc.
EL7 Factor Analysis
How we score this
Overall89
Excellent — top fifth of the marketHigh FlyerF 6/9SafeBetter than 89% of Market stocks, per EL7's model
FactorScoreDistributionValueAvgRank
▸
Valuation
23
35.3x▼17.8xBottom tier
▸
Growth
56
12.7%▲7.1%Around median
▸
Quality
73
13.8%▲4.5%Top tier
▸
Safety
90
0.3x▲2.6xTop tier
▸
Capital Return
47
0.54%▼2.12%Around median
▸
Momentum
74
34.0%▲2.9%Top tier
▸
Sentiment
94
13▲3Top tier
AME

AME AMETEK, Inc.

AMETEK, Inc. · NYSE
Market Closed
241.87
▲ ⁦+3.26%⁩ (+7.63)
Market Cap$55.4B
Beta0.99
52w Low52w High
179.24261.16
Last Week
⁦+3.72%⁩
Last Month
⁦-5.63%⁩
Last 3 Months
⁦+9.06%⁩
Last Year
⁦+29.01%⁩
Fair Value
Current price$242
Analyst target · 7 analysts
$270
⁦+12%⁩
See it undervalued
Range ⁦$230–$316⁩
vs
DCF (estimate)
$119
⁦-51%⁩
Sees it clearly overvalued
⁦8.8⁩% discount · ⁦1⁩% growth
Bottom lineThe two methods disagree — estimate range ⁦$119–$270⁩.

Estimates — analyst targets and a simplified DCF, not investment advice.

Compare in the screener
Premium content

Get Your Premium Account Now

  • Stock Deep Analysis
  • The Advanced News Platform
Recommended
Annual plan
$17/mo
Monthly plan
$29/mo

Analyst Consensus

This section combines price targets, revision history, analyst coverage changes, and an AI summary of what changed on the Street.

Price Target· 7 analysts setting price target
$271.36
⁦+12.2%⁩
Current Price $241.87·Median $270.00
Low
$230.00
High
$316.00
Current price
$241.87
Average target
$271.36
Street summary

Relative stability with a slight downward revision in consensus

The consensus price target remained stable at 271.36 from 7 analysts, unchanged over the last day. Over the last 7 and 30 days, consensus declined from 273 to 271.36, a decrease of 1.64 or 0.6%, while the number of analysts remained unchanged. Current targets range from 230 to 316, reflecting notable variation in estimates compared with the current price of 236.27.

As of 2026-09-09
Revisions momentum · 30d
⁦-0.6%⁩
Average rating
★ 3.70
Buy
Analyst coverage
20
Buy conviction
70%
High
Rating activity · 30d
0↑ · 0↓
Target dispersion
36%
Wide
Analyst ratings over time20 analysts rating
2
12
5
1
Strong BuyBuyHoldSellStrong Sell
Rating trend — last 12 months3.58 → 3.70
Recent analyst moves
  • = Reiterate2026-09-08
    Vertical Research
    Buy
  • = Reiterate2026-08-06
    TD Cowen
    Buy
  • = Reiterate2026-08-05
    RBC Capital
    Outperform
Premium content
Key Financials

Ten ratios that matter, each compared against its sector median and average — so you can see whether a number is rich or cheap relative to peers in the same sector.

StockSector medianSector averagetypical sector range
MetricValuePosition within sectorVerdict
  • P/E (TTM)
    35.31x
    5.69x45.54x
    Near median
  • Forward P/E
    28.63x
    4.57x36.58x
    Above average
  • EV / EBITDA
    22.91x
    3.43x27.47x
    Above average
  • FCF Yield
    3.3%
    -32.7%11.5%
    Strong
  • Revenue Growth YoY
    12.7%
    -10.7%43.4%
    Near median
  • EPS Growth YoY
    10.1%
    -128.3%132.7%
    Above average
  • Gross Margin
    36.4%
    8.6%54.6%
    Above average
  • ROIC
    13.8%
    -25.3%19.6%
    Strong
  • Net Debt / EBITDA
    0.34x
    0.55x4.37x
    Low debt
  • Dividend Yield
    0.5%
    0.1%4.8%
    Low
  • Payout Ratio
    18.9%
    6.6%80.8%
    Low
  • Altman Z-Score
    8.25
    -5.667.97
    Exceptional
Financial Analysis
|

Stock Analysis

AI-generated
Based on 2026-08-04 data

Company Overview

AMETEK manufactures highly engineered, specialized industrial technology solutions and generates revenue through two operating groups: Electronic Instruments Group, which includes measurement and analytical instruments and semiconductor, power, and aerospace solutions, and Electromechanical Group, which serves aerospace, defense, medical technologies, and automation. The company relies on products with substantial intellectual property and high switching costs, such as electrical simulation systems from RTDS, optical measurement solutions from Zygo, and Paragon Medical components, alongside growth through acquisitions and investment in product development.

In Q2 of fiscal year 2026, AMETEK reported record adjusted revenue of $2.04 billion, up 15% year over year, including 10% organic growth and a 5-percentage-point contribution from acquisitions. Electronic Instruments Group generated approximately $1.32 billion in revenue, or about 65% of group revenue, while Electromechanical Group generated approximately $723 million, or about 35%. According to EDGAR filings, gross profit was $735.0 million, net income was $406.9 million, and diluted earnings per share were $1.77.

Adjusted operating income in Q2 of fiscal year 2026 reached a record $544 million, and the operating margin increased to 26.6%, while the core margin expanded 110 basis points to 27.1%. The company achieved record adjusted earnings per share of $2.09, exceeding its previous guidance range of $1.96–$2.00, and free cash flow rose 37% to $452 million, representing conversion of 111% of net income. On a trailing-twelve-month basis in 2026, EDGAR data showed revenue of $7.9 billion and net income of $1.6 billion, compared with revenue of $7.4 billion and net income of $1.5 billion in fiscal year 2025.

What's Driving the Stock

  • Total orders in Q2 of fiscal year 2026 jumped 28% to a record $2.3 billion, and organic orders increased 25%, raising the backlog to $4.11 billion, up approximately 21% since the end of fiscal year 2025. The book-to-bill ratio was 1.12, and management expects to ship approximately 80% of the backlog during the twelve months following the August 4, 2026 call.
  • AMETEK raised its fiscal year 2026 guidance following its first-half results; it now expects total sales growth of approximately 10% and organic growth in the mid-to-high single-digit range. It also raised its adjusted diluted earnings per share range to $8.20–$8.30, representing growth of between 10% and 12%, from a previous range of $7.94–$8.14.
  • The company benefits from infrastructure spending related to artificial intelligence and energy; RTDS received an order from a hyperscale data center operator to test power system stability, while Zygo's precision measurement and optics solutions are incorporated into advanced chip manufacturing platforms. Management explained that artificial intelligence, military infrastructure, commercial aerospace, and energy collectively account for approximately half of AMETEK's business, while direct exposure to data centers remains too small to disclose as a separate segment.
  • Electromechanical Group achieved organic sales growth of 15% and organic order growth of 35% in Q2 of fiscal year 2026, driven by defense, Paragon Medical, and life sciences automation. Its operating income rose 32% to $191 million, while its core operating margin expanded 290 basis points to 26.2%, supported by the launch of Paragon programs and products on an optimized cost base.
  • New product vitality reached 25% in Q2 of fiscal year 2026, with specific launches including MicroFoil from Hughes-Treitler, a lightweight heat exchanger for aerospace, defense, and industrial cooling, and the A2GLF sensor from Alphasense, which the company described as the first lead-free galvanic oxygen sensor. These products support AMETEK's pricing power; management said price increases more than offset inflation and tariffs during the quarter.
  • AMETEK announced on August 26, 2026 that it had completed the all-cash acquisition of the Indicor Instrumentation portfolio for $5.0 billion. Management had explained during the August 4, 2026 call that approximately 50% of Indicor's revenue is recurring and that it is targeting cost savings of between 10% and 12% through global sourcing, shared services, and facility rationalization.

Buying & Selling Case

▲ Buying Case4 pts

  • +Performance combines double-digit organic growth with margin expansion: organic sales increased 10% in Q2 of fiscal year 2026, adjusted operating income rose 18%, and the core margin expanded 110 basis points to 27.1%. This indicates that AMETEK did not rely solely on acquisitions to achieve earnings growth.
  • +The $4.11 billion backlog provides strong revenue visibility, particularly with approximately 80% expected to ship during the twelve months following the August 4, 2026 call. Organic order growth of 25% also followed organic growth of 22% in Q1 of fiscal year 2026 and encompassed both operating groups.
  • +The quality of cash flows supports the company's ability to fund growth; free cash flow reached $452 million in Q2 of fiscal year 2026, with conversion of 111% of net income and expected annual conversion of between 110% and 115%. On June 30, 2026, the net debt-to-earnings before interest, taxes, depreciation, and amortization ratio was 0.6 times before payment for Indicor.
  • +Insider activity showed net purchases of $1 million during the three months ending with the latest transaction on August 11, 2026, with one purchase and no sales recorded. This signal remains supportive but is less important than order, cash flow, and margin growth.

▼ Selling Case

Valuation

The analyst consensus is "Buy," with an average price target of $273, a high of $316, and a low of $230; the average is approximately 4.5% above the top of the 52-week range of $261.16. The breadth of the targets from $230 to $316 reveals meaningful differences in estimates of the impact of order growth and the Indicor transaction, while the available data do not include a usable earnings multiple, so no numerical judgment about whether the stock is inexpensive or expensive can be established based on earnings.

BuyAnalyst target: $273(+12.9%)

Figures in the text are as of 2026-08-27; the live price is shown at the top of the page.

FAQ

What drove AMETEK's results in Q2 of fiscal year 2026?

Adjusted revenue reached a record $2.04 billion, up 15% year over year, with organic growth of 10% and a 5-percentage-point contribution from acquisitions. Adjusted operating income rose 18% to $544 million, and the operating margin reached 26.6%. Adjusted earnings per share were $2.09, while EDGAR filings showed net income of $406.9 million and diluted earnings per share of $1.77. Growth in semiconductors, aerospace, defense, Paragon Medical, and automation contributed to this performance.

Why is AMETEK's $4.11 billion backlog significant?

The backlog increased approximately 21% since the end of fiscal year 2025 after Q2 fiscal year 2026 orders reached $2.3 billion. The book-to-bill ratio was 1.12 and was positive in both Electronic Instruments Group and Electromechanical Group. Management expects to ship approximately 80% of the backlog during the twelve months following the August 4, 2026 call, while the fiscal year 2027 schedule has begun to fill. However, management described the timing of some orders as volatile, which may cause quarterly variation in their conversion into revenue.

How does AMETEK benefit from artificial intelligence and data centers?

RTDS sells real-time digital simulators that help data center operators test power grid stability and received an order from a hyperscale operator to support an expansion project. Zygo provides 3D measurement systems and optical components incorporated into advanced semiconductor manufacturing platforms used in artificial intelligence and next-generation computing. Internally, AMETEK began a second wave of artificial intelligence projects after a first wave that included 50 projects covering document processing, customer service, supply delay forecasting, and engineering design. Management confirmed that direct exposure to data centers is not large enough to disclose as a separate segment.

Earnings callEDGAR filings30-day newsInsider activity

Automated analysis for informational purposes only — not investment advice.

6 pts
  • −The $5.0 billion all-cash acquisition of Indicor Instrumentation represents a significant capital commitment relative to AMETEK's low net debt before the transaction. Its merits depend on successfully integrating ten businesses and achieving the targeted cost savings of between 10% and 12%, benefits that had not yet been realized at the August 4, 2026 call.
  • −Q3 fiscal year 2026 guidance indicates a slowdown from the prior quarter's pace; management expects total sales growth in the high single-digit range, following total growth of 15% and organic growth of 10% in Q2 of fiscal year 2026. Although management raised its second-half outlook, converting the backlog into revenue remains essential to maintaining the growth rate.
  • −Management acknowledged that large orders are subject to some volatility, despite orders reaching $2.3 billion and the book-to-bill ratio reaching 1.12 in Q2 of fiscal year 2026. Changes in the timing of customized engineering projects may lead to quarterly differences between order growth and revenue growth.
  • −Margins are exposed to inflation and tariff costs, even though AMETEK successfully more than offset them through pricing in Q2 of fiscal year 2026. The sustainability of this offset depends on continued pricing power in products with high switching costs and regulated markets.
  • −The company expects an effective tax rate of between 18.5% and 19% in fiscal year 2026, compared with a rate of 17.5% in Q2 of fiscal year 2026. An increase toward the annual range could limit net income growth if it is not offset by higher operating income.
  • −The 52-week range extends from $179.24 to $261.16, while the average analyst price target is $273, approximately 4.5% above the top of the range. This means reaching the consensus target assumes surpassing the highest level recorded during this period, while the available data do not provide a published earnings multiple that would allow valuation to be compared with earnings on a standardized basis.
What does the Indicor Instrumentation transaction add to AMETEK?

AMETEK announced on August 26, 2026 that it had completed the all-cash purchase of the Indicor Instrumentation portfolio for $5.0 billion. According to details presented by management on August 4, 2026, the portfolio consists of ten businesses with specialized technologies, and approximately 50% of its revenue comes from recurring sources. AMETEK is targeting cost savings of between 10% and 12% through global sourcing, shared services, and facility rationalization. Conversely, the size of the transaction increases the importance of executing the integration plan and converting the targeted savings into earnings and cash flows.

What is AMETEK's guidance for fiscal year 2026?

Management expects total sales growth of approximately 10% and organic growth in the mid-to-high single-digit range in fiscal year 2026. It raised its adjusted diluted earnings per share range to $8.20–$8.30, compared with previous guidance of $7.94–$8.14. For Q3 of fiscal year 2026, it expects total growth in the high single-digit range and adjusted earnings per share of between $2.08 and $2.10. It also maintained its free cash flow conversion forecast at 110%–115% of net income, with annual capital expenditures of approximately $160 million.

How does the performance of AMETEK's two operating groups differ?

Electronic Instruments Group generated revenue of $1.32 billion in Q2 of fiscal year 2026, up 14%, including organic growth of 7%, and its core operating margin was 30.1%. Electromechanical Group reported record revenue of $723 million, up 17%, including organic growth of 15%. Electromechanical Group's operating income rose 32% to $191 million, and its core margin expanded 290 basis points to 26.2%. Its outperformance was driven by new Paragon Medical programs and strong demand in defense, automation, and life sciences.